BTIG Maintains Buy on MDxHealth, Lowers Price Target to $2

Benzinga · 3d ago
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.